Home » Topics » Disease categories and therapies » Urology

Urology
RSS

New Lilly Icos compounds effective as PDE5 inhibitors

Feb. 20, 2002

Taisho claims compounds that inhibit the production of 20-HETE

Feb. 18, 2002

Preliminary phase IIIb results reported for transdermal oxybutynin in overactive bladder

Feb. 18, 2002

Fujisawa reveals new selective beta3-adrenoceptor agonists

Feb. 14, 2002

Compounds with PDE5-inhibitory activity disclosed by Lilly Icos

Feb. 14, 2002

The novel protein fibrocystin found to be encoded by a mutated gene in ARPKD

Feb. 13, 2002

Merck KGaA discloses compounds with PDE5-inhibitory activity

Feb. 11, 2002

Spanish lab designs selective muscarinic M3 receptor antagonists

Feb. 8, 2002

BMS and Sanofi-Synthelabo withdraw irbesartan sNDA

Feb. 8, 2002

New series from Taisho inhibits 20-HETE production

Feb. 7, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...